Duloxetine Delayed-Release Capsules, USP, 20 mg, , 500-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922, NDC 51991-746-05.
Published May 15, 2024 · Recall initiated: April 29, 2024
Summary
FDA records drug Class II recall D-0483-2024, published May 15, 2024 and initiated April 29, 2024. Recalling firm: Breckenridge Pharmaceutical, Inc; Status: Ongoing; Reported quantity: 7,188/ 500 count bottles; Lot: 220456: Exp. Feb 2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
What to do
Voluntary: Firm initiated · Letter
Get an email if DULOXETINE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- DULOXETINE
- Manufacturer
- Breckenridge Pharmaceutical, Inc
- Distributor
- US Nationwide.
- Lot
- 220456: Exp. Feb 2025
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDADuloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000June 17, 2026
- FDADuloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, Manufactured. by: TowaJune 17, 2026
- FDADuloxetine DR Capsules, 30 mg, 30 count bottles, Rx, Relabeled by: Enovachem Pharmaceuticals, Torrance, CAJune 10, 2026
- FDADuloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: Ajanta Pharma USA Inc.,May 13, 2026
- FDADuloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, (a) 90-count bottles (NDC 51991-747-90), (b)May 15, 2024
- FDADuloxetine Delayed-Release Capsules, USP, 60 mg, 90-count bottles, Rx Only, Mfr. by: Towa PharmaceuticalMay 15, 2024
Questions about this recall
Was Duloxetine Delayed-Release Capsules, USP, 20 mg, , 500-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922, NDC 51991-746-05. recalled?
Yes. FDA published recall D-0483-2024 on May 15, 2024. Reported hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: DULOXETINE.